Results 71 to 80 of about 149,933 (301)

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs   +4 more
wiley   +1 more source

Hodgkin Lymphoma and Castleman Disease: When One Blood Disease Can Hide Another

open access: yesCase Reports in Hematology, 2017
We describe a rare case of Castleman disease associated de novo with Hodgkin lymphoma. The incidence of Castleman disease is rare; only a few studies have described it in de novo association with Hodgkin lymphoma. The patient described here complained of
L. Filliatre-Clement   +4 more
doaj   +1 more source

Consumed by Abdominal Distention

open access: yes
Arthritis Care &Research, EarlyView.
Abimbola Fadairo‐Azinge   +3 more
wiley   +1 more source

Engineering Neuronal Network Connectivity Through Precise and Scalable Electrical Modulation

open access: yesAdvanced Science, EarlyView.
This study presents a scalable all‐electrical method for precise neuronal‐circuit reconfiguration based on high‐density microelectrode arrays. By employing biologically inspired plasticity rules, targeted connectivity changes were successfully induced and quantified across diverse neuronal preparations.
Sreedhar S. Kumar   +10 more
wiley   +1 more source

Rewiring NADH Metabolism Through NQO1‐Mediated Redox Cycling for Targeted Follicular Lymphoma Therapy

open access: yesAdvanced Science, EarlyView.
ABSTRACT Follicular lymphoma (FL) remains an incurable B‐cell malignancy with high relapse rates, and conventional therapies are often limited by significant toxicity, highlighting the need for novel treatments. We identified that FL exhibits markedly low expression of NAD(P)H: quinone oxidoreductase 1 (NQO1), a key enzyme required for activating ...
Jinxing Zhang   +10 more
wiley   +1 more source

Expression of Cyclooxygenase 2 and p-53 and their Relation with 5 Years Survival in Hodgkin\'s Lymphoma

open access: yesپزشکی بالینی ابن سینا, 2012
Introduction & Objective: Hodgkin lymphoma accounts for about 1% of all cancers. Cyclooxygenase 2 (COX2) is a cytoplasmic enzyme. Oncogene, and growth factor induce over expression of COX2. COX2 is apoptotic inhibitor.
Effat Abdoli   +2 more
doaj  

One-Year Follow-Up of Non-Healing Socket in Hodgkin’s Lymphoma Patient: Case Report and Literature Review on Management Strategies

open access: yesDiagnostics
Background and Clinical Significance: Sodium hypochlorite (NaOCl) is widely used in root canal treatment for its potent antiseptic and antibacterial effects.
Ahmed Ata Alfurhud
doaj   +1 more source

Hodgkin Disease (Lymphogranulomatosis) in Children

open access: yesZdorovʹe Rebenka, 2013
-
N.V. Nagornaya   +5 more
doaj   +1 more source

HBV messing with the B-cell genome leads to DLBCL [PDF]

open access: yes, 2018
non ...
Casato, Milvia, Visentini, Marcella
core   +1 more source

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on ...
Fangfang Yan   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy